Clinical Evaluation of Deferasirox For Removal of Cr+6 Ions In Rats

The present research aimed to characterize the potential efficiency of deferasirox in removing chromium after its administration for 60 days following two doses of 15 and 30 mg/kg Cr+6 to the body weight of the male Wistar rats every day. After chromium administration some abnormal clinical signs such as red staining around the eyes, greenish mottling on the liver, weakness and loss of hair and weight, were observed in rats. Deferasirox was given orally to different groups of rats for a period of one week immediately after chromium administration. After chelation therapy, animals were anesthetized with ether vapors and then chromium and iron concentrations in various tissues were determined by graphite furnace and flame atomic absorption spectrometry methods, respectively. The chelation therapy results showed that deferasirox was able to remove chromium ions from the body and at the same, iron levels in tissues and clinical symptoms were also reduced.